BioSpace News Archive

PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (“PAVmed” or the “Company”) today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented financial results for the Company for the three months ended March 31, 2023.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that preclinical research in Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio syndrome, was selected for inclusion in the Foundation for the National Institutes of Health Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (AMP® BGTC), clinical trial portfolio.

Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”) today announced financial results for the fiscal year ended December 31, 2022, and provided a business update.

Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry